Recent developments in securities, mass tort, consumer protection, and corporate law, summarized for the people they affect, with links to the primary sources.
Analysis by the firm's attorneys and briefs on public developments, with links to the primary sources. Unless stated otherwise, the firm is not counsel in the matters described. Descriptions of filed cases summarize allegations, which are not findings. Each article has its own page; follow the RSS feed for new items.
The size of the alleged fraud and the court-ordered receivership matter to defrauded investors evaluating parallel civil recovery options and illustrate continued SEC pursuit of large affinity-style investment fraud even amid an overall enforcement slowdown.
The case illustrates a continuing SEC enforcement template for affinity-style crypto fraud against retail investors that plaintiff-side counsel can reference when evaluating parallel civil recovery options for victims.
A reversal on causation-evidence grounds could raise the bar for what expert proof is sufficient to support asbestos exposure verdicts in other pending and future mesothelioma mass tort claims.
The ruling could clarify how far Delaware courts will go in imposing constructive-trust remedies against third parties, including private equity sponsors, who are found to have aided a corporate fiduciary's breach.
Listeria contamination carries documented risks of miscarriage and stillbirth for pregnant consumers, a pattern that can generate consumer-injury inquiries alongside other FDA food-safety recalls the firm tracks.
The outcome will determine whether consumers harmed by alleged generic-drug price-fixing can pursue recovery through state AG enforcement actions even after a drugmaker has settled parallel private claims, a question relevant to other multi-track price-fixing recoveries the firm tracks.
The fee request, equal to roughly a third of the fund, will shape how much of the nine-figure recovery actually reaches the millions of consumers who allege they were shorted on refunds.
The action signals continued FTC enforcement of domestic-origin advertising claims, a template plaintiff-side counsel can reference for parallel consumer-deception claims against other manufacturers making similar U.S.-origin representations.
A Class I designation covering widely used hospital infusion kits, with heightened risk to neonatal and pediatric patients, can generate product-liability and wrongful-death inquiries that plaintiff firms track alongside other FDA device recalls.
A hormone-contaminated children's oral care product recalled nationwide can generate consumer illness inquiries and potential product-liability claims the firm tracks alongside other FDA consumer-safety actions.
The decision narrows how far boards can rely on Delaware's amended Section 144 safe harbors to shield conflicted transactions from fiduciary-duty claims, a framework relevant to shareholders challenging other insider-conflicted deals.
The ruling signals that Delaware courts will personally sanction counsel, including plaintiff-side counsel, for unchecked AI-generated errors in litigation filings, a practice point relevant to the firm's own brief-drafting procedures.
A successful challenge would block a major veterinary-supply roll-up and signals continued FTC scrutiny of private equity-backed consolidation that can raise costs passed on to consumers and small businesses.
The settlement adds to a growing federal-state enforcement record on deceptive small-business payment-processing sales tactics that plaintiff-side counsel can reference in parallel private claims by merchants.
If adopted, the changes would narrow the compensation data shareholders receive, which bears directly on how plaintiff-side counsel plead and evaluate say-on-pay and executive-compensation fiduciary duty claims going forward.
A ruling could reset the pleading and liability standard for Section 11 omission claims nationwide, directly shaping how plaintiff-side counsel plead IPO-disclosure cases against issuers and underwriters going forward.
The settlement offers another benchmark for valuing spinoff-related disclosure claims that plaintiff-side counsel pursue against parent companies and their spun-off units.
The decision illustrates Delaware courts' willingness to impose substantial personal monetary liability on a founder found to have concealed information and misappropriated company assets, a precedent relevant to other founder-ouster and corporate-opportunity disputes.
The settlement is one of the FTC's largest pricing-accuracy actions against a major discount retailer and offers both a direct consumer refund mechanism and a template relevant to parallel private claims against other retailers over register-price accuracy.
The outcome could affect how aggressively the FTC can police compliance with major past privacy settlements, which bears on consumers relying on those orders for ongoing data-privacy protections.
If something happened to more people than you, tell us.
Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.